Drug Profile
Research programme: anticancer therapeutics - Phanes Therapeutics
Alternative Names: Anti-CD47 antibody - Phanes Therapeutics; Apelin-neutralizing mAbs; Apelin-neutralizing monocloncal antibodiesLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Phanes Therapeutics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; G protein-coupled receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 15 Dec 2021 Phanes Therapeutics plans to file IND application in 2022
- 21 Apr 2018 Pharmacodynamics data from a preclinical trial in cancer presented at the at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)